Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

and a new drug application (NDA) had not yet been issued. Unfortunately, since that time the 'treatment IND' option has been eliminated and the compassionate use of drugs is rarely, if ever ...

The matter was discussed during the 92nd DTAB meeting held on April 24, 2025. The Board was apprised with respect to ...

the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers.

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the ...

NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to the p53 Y220C mutant protein, improving its thermal stability, thereby ...

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s ...